Fezolinetant: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany), SMC (Scotland) and TLV (Sweden), among others, recommended or restricted fezolinetant, while AOTMIT (Poland) did not recommend it.
On the same population the two systems disagree outright: SMC (Scotland) recorded restricted for “For treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.”, while PBAC (Australia) recorded not recommended for “Moderate to severe menopause-related vasomotor symptoms (VMS)”.
The record spans 2.5 years, opening at CIPM (Spain) on 29 Jan 2024 and running to 13 Jul 2026.
CIPM (Spain) changed its position: not recommended on 29 Jan 2024, recommended by 28 Apr 2026, after a resubmission.
No assessment is on file from HAS (France) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
The file is active: 12 of 13 records date from 2023 or later.
Against its own class, fezolinetant is an outlier: 55% of its decisive outcomes were positive, where molecules sharing ATC class G02C average 79%.
4 distinct indication wordings are recorded for fezolinetant by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 13 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
CIPM (Spain) was first to assess fezolinetant, on 29 Jan 2024; SMC (Scotland) did not open a file until 13 Jul 2026 — a moderate spread of 2.5 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 5 of 12 dated records fall in 2024 alone.
3 of the 9 agencies here assessed fezolinetant more than once, CIPM (Spain) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for fezolinetant.
The full ledger for fezolinetant reads 5 not recommended, 4 recommended, 2 restricted and 1 appraised, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| ZIN (Netherlands) | 27 May 2026 | Advies - vergoed fezolinetant (Veoza®) voor de behandeling van matige tot ernstige overgangsklachten | reimbursed | source |
| NICE (England) | 31 Mar 2026 | NICE TA1143 | published appraisal | source |
| CIPM (Spain) | 17 Dec 2025 | Indicación terapéutica autorizada: Veoza está indicado para el tratamiento de los síntomas vasomotores (SVM) de moderado… | not financed by the SNS (financed 2026-04) | source |
| PBAC (Australia) | 2025 | Moderate to severe menopause-related vasomotor symptoms (VMS) | Not Recommended | source |
| AOTMIT (Poland) | 10 Dec 2024 | Veoza reimbursement recommendation | not recommended | source |
8 further decisions for fezolinetant, across 7 agencies, are not shown here. They include the most recent record on file, 13 Jul 2026 from SMC (Scotland); its outcome is in the subscriber dataset. They link to 7 further source documents.
Related molecules
- naproxen — same ATC class G02C — Other gynecologicals
- avapritinib — also decided by SMC in 2026Q3
- durvalumab — also decided by SMC in 2026Q3
- tebentafusp — also decided by SMC in 2026Q3
- glofitamab — also decided by SMC in 2026Q3
- dostarlimab — also decided by SMC in 2026Q3
Coverage: 13 decisions for fezolinetant from 9 agencies, 2024 to 2026. Data to 7 Sep 2026. ATC class G02C — Other gynecologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.